We treated mice with the PCSK9-inhibitor Alirocumab, which increased hepatic LDLR expression and reduced cholesterol levels, and subjected them to experimental myocardial infarction, while antibody-bound PCSK9 accumulated in the heart. Here, PCSK9 is linked to myocardial infarction.